BEAM vs CRSP
BEAM and CRSP side by side — valuation & fundamentals (public data).
Key statistics
| Metric | BEAMBeam Therapeutics Inc. | CRSPCRISPR THERAPEUTICS AG |
|---|---|---|
| Market cap | $2.84B | $5.00B |
| P/B | 2.98 | — |
| P/S | 20.5x | 1437.0x |
| Revenue | $146.64M(TTM) | — |
| Revenue growth (YoY) | 120.0% | -90.6% |
| Net income | -$108.35M(TTM) | — |
| Earnings growth (YoY) | 78.8% | -58.8% |
| EPS, diluted | $-0.88(TTM) | — |
| EBIT margin | -274.6% | -18933.6% |
| ROE | -8.4% | -35.3% |
| ROIC | -45.7% | -32.5% |
| 1y total return | +21.6% | -7.7% |
Figures from SEC filings · for reference only · not investment advice
$10,000 투자 성장: BEAM vs CRSP
| 지표 | BEAM | CRSP |
|---|---|---|
| 최종 가치 | $14.6K | $9.5K |
| 총수익률 | +46.1% | -5.2% |
| CAGR | +5.8% | -0.8% |
| 변동성 | 79.5% | 61.5% |
| 샤프 | 0.41 | 0.22 |
| 소르티노 | 0.63 | 0.34 |
| 최대 낙폭 | -89.1% | -85.1% |
공통 거래일 1696일 기준, 2020-02-06 → 2026-11-04 · 무위험수익률 4.21% (현재 단기 국채 금리, 고정 적용)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)